NCT04325620View on ClinicalTrials.gov

Safety to Evaluate the Efficacy and Safety of HIP1601 in Patients With Non Erosive Reflux Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

208

Participants

Timeline

Start Date

June 10, 2019

Primary Completion Date

August 3, 2020

Study Completion Date

August 3, 2020

Conditions
Non-erosive Gastroesphageal Reflux Disease
Interventions
DRUG

HIP1601

HIP1601

DRUG

HGP1805

Placebo of HIP1601

Trial Locations (1)

13620

Seoul National University Bundang Hospital, Seongnam-si

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT04325620 - Safety to Evaluate the Efficacy and Safety of HIP1601 in Patients With Non Erosive Reflux Disease | Biotech Hunter | Biotech Hunter